N A van der Gaag1, K Harmsen2, W J Eshuis2, O R C Busch2, T M van Gulik2, D J Gouma3. 1. Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: navandergaag@gmail.com. 2. Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands. 3. Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: d.j.gouma@amc.uva.nl.
Abstract
BACKGROUND: Resection is the only life-prolonging option for pancreatic or periampullary cancer. Cell-mediated immunity might reduce progression of metastasis or local recurrence likelihood, but surgery associated morbidity can suppress this immunity. The aim of this study was to examine the influence of complications on cancer specific survival after pancreatoduodenectomy (PD) for pancreatic and periampullary cancer. METHOD: 517 consecutive patients who underwent PD for pancreatic or periampullary adenocarcinoma were analysed. RESULTS: After median follow-up of 24 (14-44) months, 377 (73%) patients had died from progressive disease, 140 (27%) were alive. Median survival for pancreatic adenocarcinoma was 22 (18-25) months following an uncomplicated postoperative course versus 16 (13-19) months for patients with major surgical complications (p = 0.021). Multivariable Cox regression analysis demonstrated that microscopically residual disease (R1), complications, and adjuvant therapy were independent factors for recurrence. Within the R1 group, survival for patients with complications was even more limited, 9.7 (8.3-11.0) versus 18.7 (15.0-22.5) for those without (p < 0.001). For patients with R1 resection complications was the only independent predictor for a shorter time interval to death (hazard ratio 1.96; 95% CI 1.16-3.30). Complications did not influence survival of patients with periampullary adenocarcinoma. CONCLUSION: Complications after resection are independently related to an impaired survival following PD for pancreatic, but not periampullary cancer. The effect is even more dramatic in patients who had an R1 resection. Although the relation is not causal per se, the findings support the hypothesis of a complication-induced, compromised immunity rendering patients more susceptible for recurrent disease.
BACKGROUND: Resection is the only life-prolonging option for pancreatic or periampullary cancer. Cell-mediated immunity might reduce progression of metastasis or local recurrence likelihood, but surgery associated morbidity can suppress this immunity. The aim of this study was to examine the influence of complications on cancer specific survival after pancreatoduodenectomy (PD) for pancreatic and periampullary cancer. METHOD: 517 consecutive patients who underwent PD for pancreatic or periampullary adenocarcinoma were analysed. RESULTS: After median follow-up of 24 (14-44) months, 377 (73%) patients had died from progressive disease, 140 (27%) were alive. Median survival for pancreatic adenocarcinoma was 22 (18-25) months following an uncomplicated postoperative course versus 16 (13-19) months for patients with major surgical complications (p = 0.021). Multivariable Cox regression analysis demonstrated that microscopically residual disease (R1), complications, and adjuvant therapy were independent factors for recurrence. Within the R1 group, survival for patients with complications was even more limited, 9.7 (8.3-11.0) versus 18.7 (15.0-22.5) for those without (p < 0.001). For patients with R1 resection complications was the only independent predictor for a shorter time interval to death (hazard ratio 1.96; 95% CI 1.16-3.30). Complications did not influence survival of patients with periampullary adenocarcinoma. CONCLUSION: Complications after resection are independently related to an impaired survival following PD for pancreatic, but not periampullary cancer. The effect is even more dramatic in patients who had an R1 resection. Although the relation is not causal per se, the findings support the hypothesis of a complication-induced, compromised immunity rendering patients more susceptible for recurrent disease.
Authors: Kaitlyn J Kelly; Luke Selby; Joanne F Chou; Katerina Dukleska; Marinela Capanu; Daniel G Coit; Murray F Brennan; Vivian E Strong Journal: Ann Surg Oncol Date: 2015-01-29 Impact factor: 5.344
Authors: Savita Joglekar; Aeen Asghar; Sarah L Mott; Benjamin E Johnson; Anna M Button; Eve Clark; James J Mezhir Journal: J Surg Oncol Date: 2014-12-29 Impact factor: 3.454
Authors: M Sandini; K J Ruscic; C R Ferrone; M Qadan; M Eikermann; A L Warshaw; K D Lillemoe; Carlos Fernández-Del Castillo Journal: J Gastrointest Surg Date: 2018-09-17 Impact factor: 3.452
Authors: David P J van Dijk; Maikel J A M Bakens; Mariëlle M E Coolsen; Sander S Rensen; Ronald M van Dam; Martijn J L Bours; Matty P Weijenberg; Cornelis H C Dejong; Steven W M Olde Damink Journal: J Cachexia Sarcopenia Muscle Date: 2016-10-26 Impact factor: 12.910